کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5898710 1568794 2016 11 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Effects of linagliptin monotherapy compared with voglibose on postprandial blood glucose responses in Japanese patients with type 2 diabetes: Linagliptin Study of Effects on Postprandial blood glucose (L-STEP)
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی علوم غدد
پیش نمایش صفحه اول مقاله
Effects of linagliptin monotherapy compared with voglibose on postprandial blood glucose responses in Japanese patients with type 2 diabetes: Linagliptin Study of Effects on Postprandial blood glucose (L-STEP)
چکیده انگلیسی


- Here, we conducted a randomized prospective multicenter study that we named the Linagliptin Study of Effects on Postprandial blood glucose (L-STEP) to compare the effects of linagliptin and voglibose on postprandial hyperglycemia.
- Our data suggested that linagliptin monotherapy had a stronger glucose-lowering effect than voglibose monotherapy with respect to HbA1c and serum fasting glucose levels, but not serum glucose levels 2 h after the start of the meal tolerance test.

AimsTo compare the efficacy on glycemic parameters between a 12-week administration of once-daily linagliptin and thrice-daily voglibose in Japanese patients with type 2 diabetes.MethodsIn a multi-center, randomized, parallel-group study, 382 patients with diabetes were randomized to the linagliptin group (n = 192) or the voglibose group (n = 190). A meal tolerance test was performed at weeks 0 and 12. Primary outcomes were the change from baseline to week 12 in serum glucose levels at 2 h during the meal tolerance test, HbA1c levels, and serum fasting glucose levels, which were compared between the 2 groups.ResultsWhereas changes in serum glucose levels at 2 h during the meal tolerance test did not differ between the groups, the mean change in HbA1c levels from baseline to week 12 in the linagliptin group (−0.5 ± 0.5% [−5.1 ± 5.4 mmol/mol]) was significantly larger than in the voglibose group (−0.2 ± 0.5% [−2.7 ± 5.4 mmol/mol]). In addition, there was significant difference in changes in serum fasting glucose levels (−0.51 ± 0.95 mmol/L in the linagliptin group vs. −0.18 ± 0.92 mmol/L in the voglibose group, P < 0.001). The incidences of hypoglycemia, serious adverse events (AEs), and discontinuations due to AEs were low and similar in both groups. However, gastrointestinal AEs were significantly lower in the linagliptin group (1.05% vs. 5.85%; P = 0.01).ConclusionsThese data suggested that linagliptin monotherapy had a stronger glucose-lowering effect than voglibose monotherapy with respect to HbA1c and serum fasting glucose levels, but not serum glucose levels 2 h after the start of the meal tolerance test.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Diabetes Research and Clinical Practice - Volume 121, November 2016, Pages 146-156
نویسندگان
, , , , , , , , , , ,